
Robert Howard Glassman MD
Hematologic Oncology
Clinical Assistant Professor of Medicine. Assistant Attending Physician, NewYork-Presbyterian Hospital.
Join to View Full Profile
15 Morris Ave#326Long Branch, NJ 07740
Dr. Glassman is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Robert Glassman serves as the Executive Vice President, Search & Evaluation at Enavate Sciences, a $600M private equity fund that is a subsidiary of Patient Square Capital. Dr. Glassman also serves as a board member for Pharvaris and EluraBio and is an advisor at Centrexion.
Dr. Glassman is an industry veteran with nearly 30 years of healthcare leadership and investment experience. Most recently, he was a venture partner in public equity at OrbiMed Advisors, returning to the firm after serving as a private equity partner. Previously, he worked as a senior investment banking professional for over seventeen years across Credit Suisse, Merrill Lynch, Bank of America, most recently serving as Vice Chairman of the Global Health Care Investment Banking division at Credit Suisse. Earlier in his career, Dr. Glassman oversaw healthcare investments at Merrill Lynch Global Private Equity and was a consultant within McKinsey & Company’s Pharmaceutical and Medical Products practice. Dr. Glassman was a board-certified hematologist-oncologist and remains on the faculty of Weill Cornell as a Clinical Assistant Professor of Medicine. He also spent several years as a basic science investigator at Rockefeller University in the laboratory of Hidesaburo Hanafusa, where he received Howard Hughes Medical Institute and American Cancer Society awards. He continues to publish in peer reviewed journals on drug development, innovation, and data analysis. Dr. Glassman earned his A.B. from Harvard College and an M.D. from Harvard Medical School
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 1991 - 1994
University of Pennsylvania Health SystemResidency, Internal Medicine, 1987 - 1990
Harvard Medical SchoolClass of 1987
Certifications & Licensure
NY State Medical License 1990 - 2028
PA State Medical License 1988 - 1990
Publications & Presentations
PubMed
- Tumor cell intrinsic mechanisms of immune escape.Ganapathy Sriram, Ahmed Aquib, Robert Glassman, Raymond B Birge
Cell Communication and Signaling. 2026-04-25 - 8 citationsWhen are results of single-arm studies dramatic?Robert H. Glassman, Grace Kim, Marc J. Kahn
Nature Reviews. Clinical Oncology. 2020-11-01 - 55 citationsDoxycycline treatment of high-risk COVID-19-positive patients with comorbid pulmonary disease.Paul A. Yates, Steven A. Newman, Lauren Oshry, Robert H. Glassman, Ashton M. Leone
Therapeutic Advances in Respiratory Disease. 2020-09-01
Journal Articles
- New Cures Require New Pricing PoliciesRena Conti, Robert Glassman, and Mark Ratain, Health Affairs, 4/16/2015
Authored Content
- When are results of single arm studies dramatic?August 2020
Press Mentions
Jubilant Therapeutics Appoints Dr. Robert Glassman to Its Board of DirectorsFebruary 5th, 2021
Tarus Therapeutics Strengthens Its Board of Directors with Appointments of Mark Cohen and Robert GlassmanNovember 19th, 2020
Research History
- Postdoctoral FellowLaboratory of Hidesaburo Hanafusa1991 - 1996
Professional Memberships
- Member
- Member
- Member
- AACRMember
Industry Relationships
- Executive Vice President, Enavate SciencesVenture capital fund focused on biotechnology therapeutics2022 - Present
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









